Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells

Manabu Hirai, Drake LaFace, Simon Robinson, Linda Kelsey, Robert Johnson, Shu Fen Wen, Phyllis Irene Warkentin, Kevin Mills, Mei Vaillancourt, Jennifer Chavez, Cheryl Leutzinger, Janos Sumegi, Sarah Neugebauer, Janae Lehman, Catherine Talmadge, Dan Maneval, James E Talmadge

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Co-incubation of a replication-deficient, recombinant adenovirus carrying the wild-type p53 gene (rAd-p53) and hematopoietic stem cell (HSC) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient (SCID) mice and to undergo secondary transplantation provides the only nonclinical measure of self-renewing, stem cell function. The objective of this study was to investigate whether co-incubation with rAd-p53 compromised the SCID repopulating activity (SRA) of HSC. Granulocyte colonystimulating factor-mobilized human CD34+ cells were co-cultured with rAd-p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic (NOD)-SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte-macrophage colony-forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34+ cells co-incubated with rAd-p53 and control CD34+ cells (no rAd-p53 co-incubation). We conclude that co-incubation with rAd-p53 has little effect on the SRA of HSC.

Original languageEnglish (US)
Pages (from-to)936-947
Number of pages12
JournalCancer Gene Therapy
Volume8
Issue number12
DOIs
StatePublished - Dec 27 2001

Fingerprint

p53 Genes
Human Activities
Genetic Therapy
Hematopoietic Stem Cells
SCID Mice
Hematopoiesis
Colony-Forming Units Assay
Granulocyte-Macrophage Progenitor Cells
Granulocytes
Adenoviridae
Neoplasms
Flow Cytometry
Stem Cells
Transplantation
Breast Neoplasms
Polymerase Chain Reaction
Population

Keywords

  • Adenovirus
  • CD34
  • NOD-SCID
  • Purging
  • Repopulation
  • p53

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. / Hirai, Manabu; LaFace, Drake; Robinson, Simon; Kelsey, Linda; Johnson, Robert; Wen, Shu Fen; Warkentin, Phyllis Irene; Mills, Kevin; Vaillancourt, Mei; Chavez, Jennifer; Leutzinger, Cheryl; Sumegi, Janos; Neugebauer, Sarah; Lehman, Janae; Talmadge, Catherine; Maneval, Dan; Talmadge, James E.

In: Cancer Gene Therapy, Vol. 8, No. 12, 27.12.2001, p. 936-947.

Research output: Contribution to journalArticle

Hirai, M, LaFace, D, Robinson, S, Kelsey, L, Johnson, R, Wen, SF, Warkentin, PI, Mills, K, Vaillancourt, M, Chavez, J, Leutzinger, C, Sumegi, J, Neugebauer, S, Lehman, J, Talmadge, C, Maneval, D & Talmadge, JE 2001, 'Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells', Cancer Gene Therapy, vol. 8, no. 12, pp. 936-947. https://doi.org/10.1038/sj.cgt.7700390
Hirai, Manabu ; LaFace, Drake ; Robinson, Simon ; Kelsey, Linda ; Johnson, Robert ; Wen, Shu Fen ; Warkentin, Phyllis Irene ; Mills, Kevin ; Vaillancourt, Mei ; Chavez, Jennifer ; Leutzinger, Cheryl ; Sumegi, Janos ; Neugebauer, Sarah ; Lehman, Janae ; Talmadge, Catherine ; Maneval, Dan ; Talmadge, James E. / Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. In: Cancer Gene Therapy. 2001 ; Vol. 8, No. 12. pp. 936-947.
@article{989744efb5ea46feb4f2f134768ed610,
title = "Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells",
abstract = "Co-incubation of a replication-deficient, recombinant adenovirus carrying the wild-type p53 gene (rAd-p53) and hematopoietic stem cell (HSC) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient (SCID) mice and to undergo secondary transplantation provides the only nonclinical measure of self-renewing, stem cell function. The objective of this study was to investigate whether co-incubation with rAd-p53 compromised the SCID repopulating activity (SRA) of HSC. Granulocyte colonystimulating factor-mobilized human CD34+ cells were co-cultured with rAd-p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic (NOD)-SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte-macrophage colony-forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34+ cells co-incubated with rAd-p53 and control CD34+ cells (no rAd-p53 co-incubation). We conclude that co-incubation with rAd-p53 has little effect on the SRA of HSC.",
keywords = "Adenovirus, CD34, NOD-SCID, Purging, Repopulation, p53",
author = "Manabu Hirai and Drake LaFace and Simon Robinson and Linda Kelsey and Robert Johnson and Wen, {Shu Fen} and Warkentin, {Phyllis Irene} and Kevin Mills and Mei Vaillancourt and Jennifer Chavez and Cheryl Leutzinger and Janos Sumegi and Sarah Neugebauer and Janae Lehman and Catherine Talmadge and Dan Maneval and Talmadge, {James E}",
year = "2001",
month = "12",
day = "27",
doi = "10.1038/sj.cgt.7700390",
language = "English (US)",
volume = "8",
pages = "936--947",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells

AU - Hirai, Manabu

AU - LaFace, Drake

AU - Robinson, Simon

AU - Kelsey, Linda

AU - Johnson, Robert

AU - Wen, Shu Fen

AU - Warkentin, Phyllis Irene

AU - Mills, Kevin

AU - Vaillancourt, Mei

AU - Chavez, Jennifer

AU - Leutzinger, Cheryl

AU - Sumegi, Janos

AU - Neugebauer, Sarah

AU - Lehman, Janae

AU - Talmadge, Catherine

AU - Maneval, Dan

AU - Talmadge, James E

PY - 2001/12/27

Y1 - 2001/12/27

N2 - Co-incubation of a replication-deficient, recombinant adenovirus carrying the wild-type p53 gene (rAd-p53) and hematopoietic stem cell (HSC) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient (SCID) mice and to undergo secondary transplantation provides the only nonclinical measure of self-renewing, stem cell function. The objective of this study was to investigate whether co-incubation with rAd-p53 compromised the SCID repopulating activity (SRA) of HSC. Granulocyte colonystimulating factor-mobilized human CD34+ cells were co-cultured with rAd-p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic (NOD)-SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte-macrophage colony-forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34+ cells co-incubated with rAd-p53 and control CD34+ cells (no rAd-p53 co-incubation). We conclude that co-incubation with rAd-p53 has little effect on the SRA of HSC.

AB - Co-incubation of a replication-deficient, recombinant adenovirus carrying the wild-type p53 gene (rAd-p53) and hematopoietic stem cell (HSC) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient (SCID) mice and to undergo secondary transplantation provides the only nonclinical measure of self-renewing, stem cell function. The objective of this study was to investigate whether co-incubation with rAd-p53 compromised the SCID repopulating activity (SRA) of HSC. Granulocyte colonystimulating factor-mobilized human CD34+ cells were co-cultured with rAd-p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic (NOD)-SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte-macrophage colony-forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34+ cells co-incubated with rAd-p53 and control CD34+ cells (no rAd-p53 co-incubation). We conclude that co-incubation with rAd-p53 has little effect on the SRA of HSC.

KW - Adenovirus

KW - CD34

KW - NOD-SCID

KW - Purging

KW - Repopulation

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0035213927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035213927&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700390

DO - 10.1038/sj.cgt.7700390

M3 - Article

C2 - 11781656

AN - SCOPUS:0035213927

VL - 8

SP - 936

EP - 947

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 12

ER -